Measuring Epigenetic Age in People With Myeloproliferative Neoplasms
Measures epigenetic age in adults with myeloproliferative neoplasms and links it to complications.
Key facts
- Who runs it
- University Hospital, Bordeaux
- Where
- Bordeaux, FranceSee the site
- Trial code
- Registry title
- Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 15 Dec 2023
- Planned end
- Dec 2025
- Type of study
- Observational, 4 groups
- Treatments tested
- Assessment of the epigenetic age
- Record updated
- 30 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with polycythemia vera, essential thrombocythemia or primary myelofibrosis, plus a small group of people without a blood cancer. It studies epigenetic age (a DNA-based measure of aging).
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- For the 110 patients: polycythemia vera (PV), essential thrombocythemia (ET) or primary myelofibrosis (PMF). For the 10 people without MPN: no blood cancer; tested for the JAK2V617F mutation because of reactive thrombocytosis or secondary polycythemia.
- Earlier treatment
- No treatment that is likely to change DNA methylation, such as chemotherapy or immunosuppressants. For patients, no cytoreductive drug or demethylating agent at the time of DNA sampling.
- Biomarker or test result
- DNA from purified granulocytes taken at diagnosis must be available for the patients.
Main reasons for not taking part
- MPN patients without PV, ET or PMF
- MPN patients without purified granulocyte DNA from the time of diagnosis
- MPN patients with less than 2 years of follow-up
- Treatment with a cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
- People without MPN who have a blood cancer or a solid cancer
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- For the 110 patients with MPN:
- Patients with PV, ET or PMF
- DNA extracted from purified granulocytes at time of diagnosis
- No treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular); For the 10 subjects without MPN:
- Absence of hematological malignancy
- Search for JAK2V617F mutation in the context of reactive thrombocytosis or secondary polycythemia
- Absence of treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular)
Who cannot take part
- Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
- Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
- Patients with hematological malignancy and/or solid cancer
- For the 110 patients with MPN:
- Patients without PV, ET or PMF
- Patients without purified granulocytes DNA available at time of diagnosis
- Patients with less than 2 years' follow-up; For the 10 subjects in NMP :
Where in France
- CHU de Bordeaux, service Hématologie BiologiqueBordeaux, FranceContact: Olivier MANSIERTaking people
About the trial
What the trial wants to find out
Myeloproliferative Neoplasms (MPN) are hematological malignancies characterized by the excessive production of myeloid cells. MPN can be complicated by thrombosis and evolution into more aggressive diseases (myelofibrosis and acute leukemia). Aging remains the principal factor determining patients' survival in MPN. In recent years, DNA methylation has appeared as a mean to measure aging via the development of epigenetic clocks that have also been associated with the occurrence of thrombosis and cancer. The epiC project aims at determining epigenetic age of MPN patients and search for an association between this parameter and thrombotic/hematological complications.
The 4 groups in the trial
- Patients with ET
45 patients with ET: * 15 without thrombotic event (neither at diagnosis nor during follow-up) * 15 with thrombotic events (thrombosis at diagnosis or within 2 years of diagnosis) * 15 who progressed to myelofibrosis or AML during follow-up
Treatment: Assessment of the epigenetic age
- Patients with PV
45 patients with PV * 15 without thrombotic event (neither at diagnosis nor during follow-up) * 15 with thrombotic event (thrombosis at diagnosis or within 2 years of diagnosis) * 15 who progressed to myelofibrosis or AML during follow-up
Treatment: Assessment of the epigenetic age
- Patients with PMF
20 patients with PMF: * 10 without transformation into AML * 10 patients who progressed to AML
Treatment: Assessment of the epigenetic age
- Patients without MPN
10 patients without MPN
Treatment: Assessment of the epigenetic age
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
- Plain-language title
- Measuring Epigenetic Age in People With Myeloproliferative NeoplasmsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 July 2025